Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Siplizumab: Difference between pages

{{Short description|Monoclonal antibody}}

| verifiedrevid = 464392011

<!-- Monoclonal antibody data -->

<!-- Clinical data -->

<!-- Pharmacokinetic data -->

<!-- Identifiers -->

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 288392-69-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = KUW1QG1ZM3

<!-- Chemical data -->

'''Siplizumab''' (MEDI-507) is an investigational [[monoclonal antibody]] with a human [[IgG1]], kappa directed to [[CD2]]. The agent has shown potent [[immunomodulatory]] effects, selectively suppressing the function of [[T cell|T]] and [[NK cell]]s, and has been tested as a possible treatment for [[psoriasis]] and in the prevention of [[graft-versus-host disease]].<ref>{{cite journal |last1=Podestà |first1=Manuel A. |last2=Binder |first2=Christian |last3=Sellberg |first3=Felix |last4=DeWolf |first4=Susan |last5=Shonts |first5=Brittany |last6=Ho |first6=Siu-Hong |last7=Obradovic |first7=Aleksandar |last8=Waffarn |first8=Elizabeth |last9=Danzl |first9=Nichole |last10=Berglund |first10=David |last11=Sykes |first11=Megan |title=Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro |journal=American Journal of Transplantation |date=January 2020 |volume=20 |issue=1 |pages=88–100 |doi=10.1111/ajt.15533|doi-access=free |pmid=31319439 |pmc=6940533 }}</ref><ref>{{cite journal |last1=Langley |first1=Richard G. |last2=Papp |first2=Kim |last3=Bissonnette |first3=Robert |last4=Toth |first4=Darryl |last5=Matheson |first5=Robert |last6=Hultquist |first6=Micki |last7=White |first7=Barbara |title=Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies |journal=International Journal of Dermatology |date=July 2010 |volume=49 |issue=7 |pages=818–828 |doi=10.1111/j.1365-4632.2010.04512.x|pmid=20618506 |s2cid=21145758 }}</ref><ref>{{cite journal |last1=O'Mahony |first1=Deirdre |last2=Morris |first2=John C. |last3=Stetler-Stevenson |first3=Maryalice |last4=Matthews |first4=Helen |last5=Brown |first5=Margaret R. |last6=Fleisher |first6=Thomas |last7=Pittaluga |first7=Stefania |last8=Raffeld |first8=Mark |last9=Albert |first9=Paul S. |last10=Reitsma |first10=Dirk |last11=Kaucic |first11=Karen |last12=Hammershaimb |first12=Luz |last13=Waldmann |first13=Thomas A. |last14=Janik |first14=John E. |title=EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies |journal=Clinical Cancer Research |date=1 April 2009 |volume=15 |issue=7 |pages=2514–2522 |doi=10.1158/1078-0432.CCR-08-1254|doi-access=free |pmid=19293260 |pmc=7322623 }}</ref><ref>{{cite journal |last1=Adkins |first1=Douglas |last2=Ratanatharathorn |first2=Voravit |last3=Yang |first3=Harry |last4=White |first4=Barbara |title=Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease |journal=Transplantation |date=27 July 2009 |volume=88 |issue=2 |pages=198–202 |doi=10.1097/TP.0b013e3181abfbf7|doi-access=free |pmid=19623014 }}</ref><ref>{{cite journal |last1=Cvetkovski |first1=Filip |last2=Razavi |first2=Ronia |last3=Sellberg |first3=Felix |last4=Berglund |first4=Erik |last5=Berglund |first5=David |title=Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro |journal=American Journal of Transplantation |date=October 2023 |volume=23 |issue=10 |pages=1603–1611 |doi=10.1016/j.ajt.2023.05.032|doi-access=free |pmid=37270108 }}</ref>

== References ==

<references/>

{{immunosuppressants}}

{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]

{{monoclonal-antibody-stub}}

{{antineoplastic-drug-stub}}